Form 4: Vor Biopharma CFO Nathan D. Jorgensen Reports Changes in Beneficial Ownership
SEC Form 4 Filing
CFO of Vor Biopharma, Nathan D. Jorgensen, reports a transaction involving the withholding of shares to cover tax obligations related to restricted stock units.
Summary
- On May 6, 2024, Nathan D. Jorgensen, CFO of Vor Biopharma Inc., reported a change in beneficial ownership of common stock.
- 834 shares of common stock were disposed of to satisfy tax withholding obligations related to the settlement of restricted stock units.
- The transaction price was $1.75 per share.
- Following the transaction, Jorgensen directly owns 189,403 shares of Vor Biopharma Inc. common stock.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of a routine transaction related to executive compensation and tax obligations. It doesn't indicate positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and tax obligations. It is typical for company executives to have shares withheld to cover taxes when restricted stock units vest.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it relates to tax obligations of an executive.
Key Dates
| Date | Description |
|---|---|
| 05/06/2024 | Date of transaction involving the disposal of shares for tax withholding. |
| 05/07/2024 | Date of signature by Attorney-in-Fact. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.